FCSC - Fibrocell Science, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.7981
+0.0482 (+6.4275%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.7499
Open0.7590
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7500 - 0.8200
52 Week Range0.6100 - 4.6400
Volume3,428,919
Avg. Volume531,106
Market Cap11.748M
Beta1.18
PE Ratio (TTM)N/A
EPS (TTM)-1.8240
Earnings DateMar 7, 2018 - Mar 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.83
Trade prices are not sourced from all markets
  • ACCESSWIRE13 days ago

    Fibrocell Science Has New Capital in Hand, Updates Investors on Pipeline Products

    NEW YORK, NY / ACCESSWIRE / January 4, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Why Fibrocell Science Inc’s (NASDAQ:FCSC) Investor Composition Impacts Your Returns
    Simply Wall St.14 days ago

    Why Fibrocell Science Inc’s (NASDAQ:FCSC) Investor Composition Impacts Your Returns

    In this article, I’m going to take a look at Fibrocell Science Inc’s (NASDAQ:FCSC) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • Capital Cubelast month

    ETFs with exposure to Fibrocell Science, Inc. : December 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Fibrocell Science, Inc. Here are 5 ETFs with the largest exposure to FCSC-US. Comparing the performance and risk of Fibrocell Science, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • American City Business Journalslast month

    Chester County gene therapy company completes $10.5M stock sale

    Fibrocell Science Inc. completed its previously announced $10.5 million public stock offering on Tuesday. The Chester County gene therapy company, which is focused on developing treatments for rare skin and connective tissue diseases, sold 13.6 million shares of common stock, packaged with 14 million common warrants to purchase one additional share of common stock, at a combined price of 77 cents per share. In addition, Fibrocell granted the underwriter a 30-day option to purchase up to 2.04 million additional shares of common stock and/or warrants to purchase a common share for $0.76 per share.

  • GlobeNewswirelast month

    Fibrocell Announces Closing of $10.5 Million Underwritten Public Offering

    EXTON, Pa., Dec. 11, 2017-- Fibrocell Science, Inc., a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the closing ...

  • Should You Worry About Fibrocell Science Inc’s (FCSC) CEO Pay Check?
    Simply Wall St.last month

    Should You Worry About Fibrocell Science Inc’s (FCSC) CEO Pay Check?

    John Maslowski took the helm as Fibrocell Science Inc’s (NASDAQ:FCSC) CEO and grew market cap to USD$9.98M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • SmarterAnalystlast month

    Fibrocell Science Inc (FCSC) Feels the Heat of Share Dilution

    After pricing an equity offering that will dilute current investors but help shore up its balance sheet, shares in Fibrocell Science Inc (NASDAQ:FCSC) are tumbling 20% as of 10:30AM EST. The gene therapy company announced today the pricing of an underwritten public offering of 13,636,364 shares of its common stock and common warrants to purchase up to an aggregate of 13,636,364 shares of Common Stock (the Offering). Each share of Common Stock is being sold together with a common warrant to purchase one share of Common Stock at a combined effective price to the public of $0.77 per share and accompanying common warrant.

  • GlobeNewswirelast month

    Fibrocell Announces Pricing of $10.5 Million Underwritten Public Offering

    EXTON, Pa., Dec. 07, 2017-- Fibrocell Science, Inc., a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the pricing ...

  • Was Fibrocell Science Inc’s (FCSC) Earnings Growth Better Than Industry?
    Simply Wall St.2 months ago

    Was Fibrocell Science Inc’s (FCSC) Earnings Growth Better Than Industry?

    Examining Fibrocell Science Inc’s (NASDAQ:FCSC) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...

  • Associated Press2 months ago

    Fibrocell Science reports 3Q loss

    On a per-share basis, the Exton, Pennsylvania-based company said it had a loss of 2 cents. Losses, adjusted for non-recurring gains, were 34 cents per share. The company's shares closed at $1.76. A year ...

  • GlobeNewswire2 months ago

    Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights

    EXTON, Pa., Nov. 13, 2017-- Fibrocell Science, Inc., a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial ...

  • ACCESSWIRE2 months ago

    Fibrocell Science, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 13, 2017 / Fibrocell Science, Inc. (NASDAQ: FCSC ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 13, 2017 at 8:30 AM Eastern ...

  • Intrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss
    Zacks2 months ago

    Intrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss

    Intrexon (XON) reported narrower-than-expected loss but revenues missed estimates in the third quarter of 2017. The company remains focused on the development of its pipeline candidates.

  • The Wall Street Journal2 months ago

    New Skin for 7-Year-Old Boy Marks Advance in Gene Therapy

    In a significant advance in organ regeneration and gene therapy, researchers created a new, healthy skin that covers almost the entire body of a 7-year-old boy with a life-threatening genetic disorder ...

  • GlobeNewswire2 months ago

    Fibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third Quarter 2017 Financial Results and Recent Operational Highlights

    EXTON, Pa., Nov. 06, 2017-- Fibrocell Science, Inc., a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results ...

  • Implied Volatility Surging for Fibrocell Science (FCSC) Stock Options
    Zacks4 months ago

    Implied Volatility Surging for Fibrocell Science (FCSC) Stock Options

    Investors need to pay close attention to Fibrocell Science (FCSC) stock based on the movements in the options market lately.

  • Associated Press5 months ago

    Fibrocell Science reports 2Q loss

    On a per-share basis, the Exton, Pennsylvania-based company said it had a loss of 97 cents. Losses, adjusted for non-recurring costs, came to 31 cents per share. The company's shares closed at $3.35. A ...

  • ACCESSWIRE5 months ago

    Investor Network: Fibrocell Science, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2017 / Fibrocell Science, Inc. (NASDAQ: FCSC ) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, August 9, 2017 at 8:30 ...

  • What's in Store for Intrexon (XON) in this Earnings Season?
    Zacks6 months ago

    What's in Store for Intrexon (XON) in this Earnings Season?

    Intrexon Corporation (XON) will focus on the development of its pipeline candidates- FCX-013, FCX-007 in Q2.